{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-29",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Columbus",
      "state": "OH",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "88734",
      "recalling_firm": "American Health Packaging",
      "address_1": "2550 John Glenn Ave Ste A",
      "address_2": "N/A",
      "postal_code": "43217-1188",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "N/A",
      "distribution_pattern": "Nationwide within the USA",
      "recall_number": "D-0020-2022",
      "product_description": "GlipiZIDE Extended-Release Tablets, 2.5 mg, 30 Tablets (3 blister cards each with 10 individually blistered doses), Rx only, Manufactured by: Patheon Pharmaceuticals Inc., Cincinnati, OH 45237; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054.  Carton NDC#: 68084-295-21 (Individual Dose NDC: 68084-295-11)",
      "product_quantity": "2,266 cartons",
      "reason_for_recall": "Failed Dissolution Specifications: results were above specification.",
      "recall_initiation_date": "20210917",
      "center_classification_date": "20211020",
      "termination_date": "20230608",
      "report_date": "20211027",
      "code_info": "Lot #: 194141, Exp. Date 03/31/2022"
    }
  ]
}